Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

1 Feb 2010

Abstract excerpt

Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various clinical features. Patients with MDS, in particular those with intermediate-2 (Int-2) and high-risk disease, have a poor prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care. Over the last decade, promising results from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20616953
DOI: 10.2147/ott.s7222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesPMID 20616953Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Demethylating agents in myeloid malignanciesSemantic proximity Read ↗

Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabineSemantic proximity Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

DecitabineSemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.